Sonoma Pharmaceuticals Total Current Liabilities Over Time
| SNOA Stock | USD 2.92 0.01 0.34% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Sonoma Pharmaceuticals Performance and Sonoma Pharmaceuticals Correlation. Sonoma |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 20.967 | Quarterly Revenue Growth (0.01) | Return On Assets (0.20) | Return On Equity (0.75) |
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Current Liabilities Analysis
Compare Sonoma Pharmaceuticals and related stocks such as China Pharma Holdings, Universe Pharmaceuticals, and Acorda Therapeutics Total Current Liabilities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CPHI | 673.5 K | 13.8 M | 14.6 M | 12 M | 14.2 M | 12.8 M | 10.4 M | 9.2 M | 10.1 M | 10 M | 11.4 M | 10.5 M | 12.7 M | 6.8 M | 9.2 M |
| UPC | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 5.5 M | 8 M | 11.2 M | 13.1 M | 13.8 M | 15.8 M | 12.8 M |
| AKAN | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 8.3 M | 9.3 M | 10.2 M | 8.4 M |
| PTPI | 38.5 M | 38.5 M | 38.5 M | 38.5 M | 38.5 M | 38.5 M | 38.5 M | 38.5 M | 38.5 M | 41.1 M | 41.9 M | 31 M | 7.1 M | 10.8 M | 10.2 M |
| SBFM | 1.5 K | 3.4 K | 64.4 K | 39 K | 531 K | 1.3 M | 274.1 K | 751.1 K | 912.5 K | 833.5 K | 1.1 M | 91.2 K | 6.9 M | 5.6 M | 5.8 M |
| TKNO | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 5.6 M | 4 M | 7.7 M | 10.9 M | 8.9 M | 8.1 M |
| SXTC | 5.5 M | 5.5 M | 5.5 M | 5.5 M | 5.5 M | 5.5 M | 3.6 M | 4.4 M | 6.3 M | 12.3 M | 18.6 M | 17.1 M | 14.5 M | 8.9 M | 11.1 M |
| SHPH | 4.6 K | 4.6 K | 4.6 K | 4.6 K | 4.6 K | 4.6 K | 105.3 K | 593.8 K | 593.8 K | 2.1 M | 2.1 M | 2.2 M | 975.7 K | 1 M | 1.1 M |
| LFCR | 1.4 M | 66.7 M | 50.8 M | 48.4 M | 56.2 M | 56.5 M | 51.5 M | 88.4 M | 137.1 M | 164.4 M | 101.9 M | 79.2 M | 79.4 M | 38.9 M | 55 M |
| DERM | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 25.9 M | 35 M | 105.4 M | 38.6 M | 20.9 M | 28.1 M | 51.6 M | 66.8 M | 41.9 M | 46.9 M |
Sonoma Pharmaceuticals and related stocks such as China Pharma Holdings, Universe Pharmaceuticals, and Acorda Therapeutics Total Current Liabilities description
Total Current Liabilities is an item on Sonoma Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Sonoma Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.My Equities
My Current Equities and Potential Positions
| Sonoma Pharmaceuticals | SNOA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.92
Check out Sonoma Pharmaceuticals Performance and Sonoma Pharmaceuticals Correlation. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Sonoma Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.